Filing Flows › Bioventus (BVS) › Q2 2026 › vs Q2 2025
Bioventus (BVS) Q2 2026 vs Q2 2025 (year over year)
Bioventus's revenue rose $5.5M (+4%) from $148M in Q2 2025 to $153M in Q2 2026. Gross margin 69.0% against 69.1% (-0.2 pts).
Bioventus, Q2 2026: revenue $153M (+4% year over year), operating margin 12.5%, net earnings $33.4M, operating cash flow $19.9M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 69.0% | 69.1% | -0.2 pts |
| Operating margin | 12.5% | 12.4% | +0.0 pts |
| Net margin | 21.8% | 5.1% | +16.8 pts |
| Free cash flow margin | 12.3% | 17.1% | -4.8 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $153M | $148M | $5.5M | +4% |
| Gross profit | $106M | $102M | $3.6M | +4% |
| Cost of revenue | $47.5M | $45.6M | $2.0M | +4% |
| Operating profit | $19.1M | $18.4M | $759K | +4% |
| Operating expenses | $86.5M | $83.7M | $2.8M | +3% |
| Pre-tax earnings | $15.3M | $10.3M | $5.0M | +48% |
| Other expense, net | $3.8M | $8.1M | −$4.2M | -53% |
| Research & development | $3.2M | $3.2M | $1K | 0% |
| SG&A | $82.7M | $79.1M | $3.6M | +5% |
| Other operating costs | $626K | $1.4M | −$814K | -57% |
| Income tax benefit | $20.9M | −$1.0M | $21.9M | — |
| Net earnings | $33.4M | $7.5M | $26.0M | +348% |
| Minority interests | $2.8M | $1.8M | $951K | +52% |
| Depreciation & amortization | $10.9M | $12.0M | −$1.1M | -9% |
| Share-based compensation | $5.0M | $3.6M | $1.4M | +38% |
| Working capital & other | $29.6M | −$2.8M | $32.3M | — |
| Operating cash flow | $19.9M | $25.9M | −$6.1M | -23% |
| Free cash flow (OCF − capex) | $18.9M | $25.3M | −$6.3M | -25% |
| Capital expenditures | $960K | $683K | $277K | +41% |
Questions
How much did Bioventus's revenue grow year over year in Q2 2026?
Bioventus's revenue rose $5.5M (+4%) from $148M in Q2 2025 to $153M in Q2 2026. Gross margin 69.0% against 69.1% (-0.2 pts).